Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Datopotamab Deruxtecan vs Docetaxel in Previously Treated Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
2020-004643-80Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Progression-free survival and Overall survival. Started Dec 2020; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004643-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004643-80.